Table 1B. Bibliometric overviews of preclinical studies and ongoing trials with GLP-1R agonists and DPP-4 inhibitors in stroke (B. Ongoing clinical trials).
| Substance | EU CTR Identifier no. | CT.gov Identifier no. | Study | Planned size | Primarily stroke trial | # |
|---|---|---|---|---|---|---|
| Exenatide (GLP-1R) | 2011-002780-16 | — | Prehospital study, hyperglycemic patients with suspected stroke | 100 | * | 1 |
| Exenatide (GLP-1R) | 2013-001558-87 | — | Exenatide in patients receiving thrombolytic therapy for stroke | 40 | * | 2 |
| Exenatide (GLP-1R) | 2010-021069-63 | NCT01144338 | EXSCEL trial. Diabetics given exenatide as add on, CV events evaluated | 14,000 | 3 | |
| Exenatide (GLP-1R) | 2012-002219-25 | NCT01455896 | Diabetics, exenatide given with s.c. pump, CV events evaluated | 3,000 | 4 | |
| Liraglutide (GLP-1R) | 2011-003572-36 | — | Nil by mouth stroke patients. Stroke volume measured by MRI | 40 | * | 5 |
| Liraglutide (GLP-1R) | 2009-012201-19 | NCT01179048 | LEADER trial. Diabetics, time to CV event primary outcome. Effect and safety | 8,754 | 6 | |
| Saxagliptin (DPP-4) | No ongoing studies in both databases | 7 | ||||
| Alogliptin (DPP-4) | No ongoing studies in both databases | 8 | ||||
| Sitagliptin (DPP-4) | 2008-006719-20 | NCT00790205 | TECOS trial. Diabetics, time to CV events evaluated | 14,757 | 9 | |
| Linagliptin (DPP-4) | 2011-004148-23 | NCT01897532 | CARMELINA trial. Diabetics, time to CV events evaluated | 10,790 | 10 | |
| Linagliptin (DPP-4) | 2009-013157-15 | NCT01243424 | CAROLINA trial. Diabetics, time to CV event evaluated | 6,000 | 11 |
Abbreviations: CV, cardiovascular; DPP-4, dipeptidyl-peptidase 4; GLP-1R, glucagon-like peptide-1 receptor; MRI, magnetic resonance imaging.
EU Clinical Trial Register (EU CTR) and ClinicalTrials.gov (CT.gov) databases searched with query ‘stroke'+'substance' on 2014 November 8. Each row constitutes a unique study. Retrospective noninterventional studies excluded.